Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
With
National Cancer Institute (NCI)
OBJECTIVES:
* To describe the pharmacokinetics of prolonged intravenous infusions of fentanyl citrate in adult patients with cancer.
OUTLINE: Patients undergo blood sample collection before and after discontinuation of fentanyl citrate therapy (10 days total). Pharmacokinetic analysis is performed on the samples.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Diagnosis of cancer
Inpatient at the Johns Hopkins Hospital Cancer Center undergoing pain treatment with continuous infusion fentanyl citrate for ≥ 5 days
PATIENT CHARACTERISTICS:
Willing to change to an alternative opioid
PRIOR CONCURRENT THERAPY:
See Disease Characteristics
At least 72 hours since transdermal fentanyl citrate administration
At least 12 hours since transmucosal fentanyl citrate administration
No known requirement for continued opioid therapy with any fentanyl citrate products after discontinuation of fentanyl citrate therapy
